Yi W. Luo

79 Qingchun Road
Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 213 publications

Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms.

Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms.

Journal: Cell transplantation

Published: July 22, 2026

Pre-transplant Clostridioides difficile infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Pre-transplant Clostridioides difficile infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Journal: Cell transplantation

Published: June 13, 2026

A ribosomal protein-rich tumor cell supernatant as a potent inducer of macrophage polarization for synergistic antitumor chemotherapy.

A ribosomal protein-rich tumor cell supernatant as a potent inducer of macrophage polarization for synergistic antitumor chemotherapy.

Journal: Biomaterials

Published: May 24, 2026

Kuanxiong aerosol protects against coronary microvascular dysfunction through improving angiogenesis via HIF-1α-ITGAX axis.

Kuanxiong aerosol protects against coronary microvascular dysfunction through improving angiogenesis via HIF-1α-ITGAX axis.

Journal: Frontiers in pharmacology

Published: May 18, 2026

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial.

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: March 20, 2026

Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial.

Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial.

Journal: The Lancet regional health. Western Pacific

Published: March 18, 2026

Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.

Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.

Journal: Blood advances

Published: February 27, 2026

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Journal: American journal of ophthalmology

Published: February 24, 2026

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Cell transplantation

Published: February 12, 2026

Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial.

Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial.

Journal: Cancer

Published: February 08, 2026

Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

Journal: Blood cancer journal

Published: January 12, 2026

A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology

Published: December 29, 2025

Showing 1-12 of 213

Last Updated: 09/26/2026